

29 June 2023

ASX Announcement

## Firebrick Update on AAT Schedule

---

**Firebrick Pharma Limited (ASX:FRE) (Firebrick, Company)** is pleased to announce that in relation to the ongoing Administrative Appeals Tribunal (AAT) process for Nasodine® Nasal Spray, a conciliation meeting date has now been set for 19 July 2023. The meeting will take place in Sydney.

This announcement was authorised for release by Dr Peter Molloy, Executive Chairman, Firebrick Pharma Limited.

- ENDS -

### About Firebrick (ASX:FRE)

Firebrick is a pharmaceutical company founded with the mission to commercialise a nasal spray treatment for the common cold based around the potential of povidone-iodine as a broad-spectrum antimicrobial agent. The Company owns numerous granted and pending patents, including a core patent family that covers the use of intranasal povidone-iodine for the treatment and prevention of the common cold and a second patent family covering the prevention of pandemic viral diseases, including COVID-19. The Company also has a third patent family covering the Nasodine formulation, which has been granted in Australia. Firebrick is completing a second Phase 3 trial for Nasodine, to confirm its efficacy as a treatment for the common cold and support international approvals.

**Media enquiries:**

Heidi Cuthbert  
+61 411 272 366  
heidi.cuthbert@multiplier.com.au

**Investor enquiries:**

Investors@firebrickpharma.com